You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Neuro Devices, Inc. Topic: 100
The Bumps: A Device for Rapid, Non-Invasive Quantification of Touch Sensation Abstract !Our proposal describes an elegant device called the Bumps that quantifies finger pad touch sensation at low micron levels. The objectives are to diagnose peripheral neuropathy near its onset, when the possibility for reversal is highest, and to monitor either progression or reversal of neuropathy during treatme ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Inheret, Inc Topic: NCI
Project Summary This project is to complete the developmentintegration with the electronic medical record and human testing of the InheRET Inherited Risk Evaluation ToolInheRET s aim is to quickly and easily identify individuals at increased risk for hereditary diseasesthereby facilitating their to access downstream risk appropriate carereducing morbidity and mortalityInheRET s unique features red ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Z-Quick, LLC Topic: NIAID
Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinomaSBC: Avenzoar Pharmaceuticals, Inc. Topic: 102
ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC Topic: 500
Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health